Free Trial
NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

$147.11
-5.06 (-3.33%)
(As of 10:21 AM ET)
Today's Range
$146.54
$151.22
50-Day Range
$142.67
$174.32
52-Week Range
$126.97
$225.23
Volume
26,975 shs
Average Volume
233,234 shs
Market Capitalization
$14.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$250.75

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
68.9% Upside
$250.75 Price Target
Short Interest
Healthy
1.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of BeiGene in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.24) to ($3.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

487th out of 912 stocks

Pharmaceutical Preparations Industry

227th out of 434 stocks

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

New Government Policy to Wipe Out Seniors Wealth
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.
BeiGene (NASDAQ:BGNE) Shares Gap Up to $150.50
BeiGene (NASDAQ:BGNE) Shares Gap Down to $147.04
New Government Policy to Wipe Out Seniors Wealth
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/15/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
10,600
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$250.75
High Stock Price Target
$345.00
Low Stock Price Target
$152.50
Potential Upside/Downside
+64.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-881,710,000.00
Pretax Margin
-26.51%

Debt

Sales & Book Value

Annual Sales
$2.46 billion
Book Value
$37.10 per share

Miscellaneous

Free Float
89,703,000
Market Cap
$14.75 billion
Optionable
Optionable
Beta
0.59

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • BeiGene has shown strong revenue growth, with a 67.9% increase in quarterly revenue on a year-over-year basis, indicating a positive trend in the company's financial performance.
  • Positive earnings surprises, such as beating analysts' consensus estimates by $0.66 in the latest quarterly report, can attract investor interest and confidence in the company's potential for profitability.
  • BeiGene's stock price has been trading up recently, showing a 1.6% increase, which may signal positive market sentiment and potential for further stock price appreciation.
  • Institutional investors, including well-known firms like Price T Rowe Associates Inc. MD and Capital International Ltd. CA, have been increasing their holdings in BeiGene, indicating confidence from large investors in the company's future prospects.
  • Analysts have given BeiGene a consensus rating of "Moderate Buy" with a target price of $251.93, suggesting that there is optimism among experts regarding the company's growth potential.

Cons

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • BeiGene currently has a negative price-to-earnings ratio of -20.61, which may indicate that the stock is overvalued compared to its earnings, potentially posing a risk for investors looking for profitable returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, July 6, 2024. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BGNE Stock Analysis - Frequently Asked Questions

How have BGNE shares performed this year?

BeiGene's stock was trading at $180.36 at the beginning of 2024. Since then, BGNE stock has decreased by 17.7% and is now trading at $148.43.
View the best growth stocks for 2024 here
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($2.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.07) by $0.66. The business's quarterly revenue was up 67.9% on a year-over-year basis.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's top institutional shareholders include Simplicity Wealth LLC (0.01%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Ltd Beigene, Chan Henry Lee, Corazon (Corsee) D Sanders, Jane Huang, Xiaobin Wu, Lai Wang, Xiaodong Wang, John Oyler and Julia Aijun Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD) and Intel (INTC).

This page (NASDAQ:BGNE) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners